Value through Innovation26 November 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
21.11.2014

Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

- For media outside UK, US and Canada
19.11.2014

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

- For Non-US/Non-UK/Non-Canadian Media
19.11.2014

New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

- For Non-US/Non-UK/Non-Canadian Media
14.11.2014

Boehringer Ingelheim "Runs" to support vital programs in Diabetes and Stroke

07.11.2014

New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy

- For Media In Asian Countries Only For Whom The Data Is Relevant For media outside the US, the UK & Canada only
04.11.2014

Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva® Respimat® in asthma

- For media outside the US, the UK & Canada only
03.11.2014

FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice

- Non-US/Non-UK/Non-Canadian Media
29.10.2014

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries

21.10.2014

Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments

- For Ex-US and Ex-UK Media Only
20.10.2014

Winners of the 2014 European PRRS Research Award announced

16.10.2014

Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis

 

- For media outside UK, US and Canada
30.09.2014

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund

27.09.2014

Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

- For Ex-US and Ex-UK Media Only
27.09.2014

Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

- For Ex-US and Ex-UK Media Only
26.09.2014

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung

- For media outside UK and US only
18.09.2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

- For Ex-US and Ex-UK Media Only
16.09.2014

Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

- For Non-U.S. and Non-UK Media
10.09.2014

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

- For Non-U.S. and Non-U.K. Media
back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16